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p53 is a tumor suppressor protein whose function is
frequently lost in cancers through missense muta-
tions within the Tp53 gene. This results in the expres-
sionof point-mutatedp53proteins that haveboth lost
wild-type tumor suppressor activity and show gain of
functions that contribute to transformation and
metastasis. Here, we show that mutant p53 expres-
sion can promote invasion, loss of directionality of
migration, and metastatic behavior. These activities
of p53 reflect enhanced integrin and epidermal
growth factor receptor (EGFR) trafficking, which
depends on Rab-coupling protein (RCP) and results
in constitutive activation of EGFR/integrin signaling.
We provide evidence that mutant p53 promotes cell
invasion via the inhibitionof TAp63, andsimultaneous
loss of p53 and TAp63 recapitulates the phenotype of
mutant p53 in cells. These findings open the possi-
bility that blocking alpha5/beta1-integrin and/or the
EGF receptor will have therapeutic benefit in mutant
p53-expressing cancers.
INTRODUCTION
Wild-type p53 is activated in response to oncogenic stress
signals and functions primarily to prevent cancer development
(Vogelstein et al., 2000). To a large part, this activity of p53 is
mediated by its ability to function as a transcription factor and
induce a permanent inhibition of cell growth, through the activa-
tion of either senescence or apoptotic cell death (Vousden and
Prives, 2009). The p53 gene is mutated in around 50% of all
human cancers and even those cancers that retain wild-type
p53 frequently show defects in the pathways leading to its acti-
vation (Vogelstein et al., 2000). Thus almost all cancers have
defects in the p53 response, underscoring the importance of
loss of wild-type p53 activity for successful tumor development.
Consistent with this, mice deleted of p53 are highly cancer prone
(Attardi and Jacks, 1999).CIt is clear that a key consequence of p53 mutation is the loss of
wild-type p53 activity. However, in contrast to the loss-of-func-
tion mutations that occur in most other tumor suppressors,
p53 commonly suffers point mutations resulting in the expres-
sion of a full-length protein with a single amino acid substitution
(Petitjean et al., 2007). These mutations tend to be clustered at 6
hot spots within the central sequence-specific DNA-binding
region of the protein and result in loss of DNA binding, either
by mutation of a DNA-contacting residue (such as amino acid
273) or by perturbing the structure of the DNA-binding domain
(such as mutations at residue 175) (Cho et al., 1994). Although
expressed at low levels in normal tissue, these mutant p53
proteins are frequently stabilized and expressed at high levels
in tumors—indeed high expression of p53 in cancer tissue is
predictive of the presence of mutant p53 (Lane, 1994).
Inactivating point mutations of p53 may be selected in cancers
because they act as trans-dominant inhibitors of wild-type p53
coexpressed in the same cell (Blagosklonny, 2000). However,
there is also clear evidence that mutant p53 proteins acquire
a transforming activity that is independent of wild-type p53
and so constitutes a gain of function (Sigal and Rotter, 2000).
Studies in mice confirmed that mutation of p53 is not equivalent
to p53 loss and showed that mutant p53 can drive the develop-
ment of different types of tumors with a more invasive phenotype
than those that arise following loss of p53 (Lang et al., 2004; Olive
et al., 2004). Similarly, in human cancers mutant p53 expression
has been linked with a poorer prognosis (Petitjean et al., 2007).
This new appreciation of mutant p53 function raises the possi-
bility that the mutant protein may be a good target for the design
of novel therapies aimed at inhibiting cancer dissemination,
rather than the appearance of the primary tumor. Critical to
such approaches will be an understanding of how mutant p53
drives this invasive behavior.
In this study we have identified a key mechanism by which
mutant p53 can promote invasive behavior of cells, through
a gain of function that is independent of the loss of wild-type
p53 function. We show that mutant p53 can drive both random
cell motility and increased invasiveness through the enhance-
ment of integrin recycling pathways that have been shown
previously to promote invasive behavior (Caswell et al., 2007,
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Figure 1. Mutant p53 Expression Drives Invasion In Vitro and In Vivo
(A and B) Expression of mutant p53 in polyclonal vector control and mutant p53 (175H and 273H) H1299 (A) and RPE (B) cells assessed by western blot (left
panels). Actin expression was used as loading control in a parallel blot. The invasion of mutant p53 H1299 cells into fibronectin-supplemented Matrigel was quan-
tified (middle panel and right panel) as described in the Experimental Procedures. Values are means ± standard error of the mean (SEM) of 18 replicates from three
independent experiments. * indicates p < 0.05 as determined by a Student’s t test.
(C) Expression of p53 in MCF10A cell lines containing a vector control or mutant p53 175H (left panel). These cells were seeded into collagen 1-supplemented
Matrigel (second panel, scale bars represent 100 mm) and the number of invasive structures was quantified (third panel, measurements of at least 15 individual
acini in three independent experiments). Invasion of MCF10A or ErbB2-expressing MCF10A cells after infection with control (ctr) or mutant p53 175H vectors was
examined using Matrigel-coated chambers (right panel). These data represent 3–5 independent experiments.
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RESULTS
Expression of Tumor-Derived Mutant p53 Proteins
Promotes Invasive Behavior in Cancer and Normal Cells
In light of in vivo studies suggesting that mutant p53 can drive
enhanced metastasis, we examined the consequences of
mutant p53 expression in a number of tissue culture systems
that model such behavior. Initially, H1299 lung cancer cells
were employed because they are null for p53 expression and
thus preclude the possibility that any effects of mutant p53 are
due to the dominant-negative inhibition of wild-type p53. Poly-
clonal cell lines were established that stably express p53
mutants frequently found in human cancers—either p53 175H
or p53 273H—and these were compared to polyclonal H1299
cells transfected with an empty vector construct (Figure 1A, left
panel). Wild-type p53 was not included in these assays because
its expression resulted in cell-cycle arrest and apoptosis, with
only rare outgrowth of p53-expressing cells that are likely to
have undergone alterations to allow them to tolerate any wild-
type p53 expression. Analysis of the ability of these cells to
invade into fibronectin-supplemented reconstituted basement
membrane (Matrigel) showed that expression of either p53
mutant significantly enhanced their migration (Figure 1A).
Increased migration was also evident following transient expres-
sion of mutant p53, indicating that invasiveness was not acquired
indirectly during the establishment of the stably expressing cell
populations (Figure S1A available online). To establish whether
mutant p53 expression could drive invasion in other cell types,
we examined untransformed human epithelial cell systems. A
series of polyclonal TERT-immortalized human retinal pigment
epithelial (RPE) cells expressing either p53 175H or p53 273H
were established and compared to cells transfected with an
empty vector. Despite ectopic expression from a cytomegalo-
virus (CMV) promoter, the levels of p53 protein in the stable
mutant p53 transfected cells were not higher than endogenous
wild-type p53 expression (Figure 1B). As seen with the H1299
cells, expression of mutant p53 promoted the invasion of RPE
cells into Matrigel (Figure 1B). We also examined the effects of
stable expression of mutant p53 in MCF10A cells, a primary
mammary epithelial cell line (Figure 1C). These cells form
growth-arrested structures—also termed acini—when cultured
in Matrigel supplemented with collagen (Figure 1C, second
panel). After oncogenic stimulation such as expression of
V12Ras or ErbB2 (NeuT) or coexpression of ErbB1 and TGF-b,
these cells can be induced to form invasive structures (Muthusw-
amy et al., 2001; Seton-Rogers et al., 2004). Similar invasive
structures were formed in cells expressing the 175H mutant of
p53 (Figure 1C, third panel), and there was a slight enhancement
in their invasion into Matrigel (in Boyden chamber assays), which(D) Invasion of tumors arising inAhCre APCfl/+ p53fl/+ mice and AhCre APCR172H/+
(Log-Rank p = 0.815).
(E and F) Representative photomicrographs of invasive tumors seen in the AhCre A
extension of the tumor to the junction between the longitudinal and circumferentia
throughout the full thickness of the muscle wall (both H&E, 1003).
(G and H) p53 staining demonstrating accumulation of nuclear mutant p53 in one
mice (p53 immunohistochemistry, 4003).
See also Figure S1.
Cwas strongly augmented by coexpression of ErbB2 (Figure 1C,
right panel). Taken together, these studies showed that mutant
p53 proteins drive invasion and migration in a number of cell
culture models.
The oncogenic and metastatic potential of H1299 cells as
xenografts in vivo was assessed following injection into the
mammary fat pad of nude mice (Figure S1B). As described previ-
ously (Cantor et al., 2007), H1299 cells are tumorigenic in this
model, with primary tumors arising after 30 days. Tumors origi-
nating from mutant p53-expressing cells were more invasive
than those formed from control cells (Figure S1B), and microme-
tastases in the lung were only detected in mice that had been
injected with cells expressing mutant p53 (Figure S1C). These
results are consistent with studies showing a similar role for
mutant p53 in xenograft studies (Adorno et al., 2009) and in
mice expressing mutant p53 in all tissues (Lang et al., 2004; Olive
et al., 2004). To investigate the effect of targeted expression of
mutant p53 in the adult mouse more closely, we generated
mice with intestine-specific alterations in APC and Tp53 (San-
som et al., 2004). Here AhCre transgenic mice carrying a single
conditional inactivatable Apcfl/+ allele were intercrossed to
mice carrying either an inducible knockout Tp53 allele (AhCre
APCfl/+, Tp53fl/+) or an inducible knockin allele of mutant p53
(AhCre APCfl/+, Tp53172H/+). In this model, intestinal tumor
formation is associated with the loss of the remaining wild-type
Apc allele (Sansom et al., 2006). Both cohorts of mice developed
intestinal tumors with similar incidence and latency (Log Rank
p = 0.815), but there was a clear difference in incidence of inva-
sive adenocarcinomas. Coordinate deletion of one allele of APC
and Tp53 gave rise to primarily intestinal adenomas, with
evidence of invasive adenocarcinomas in only 25% of mice
(Figure 1D), similar to that seen previously in APCfl/+ Tp53+/+
mice (Marsh et al., 2008; Sansom et al., 2006). However, all
mice where mutant p53 was introduced (AhCre APCfl/+,
Tp53172H/+) developed invasive tumors (Figures 1D–1F) with
pronounced nuclear staining for mutant p53 (Figures 1G and
1H). These results support the ability of mutant p53 (as opposed
to loss of p53) to enhance invasion and metastasis.
Mutant p53 Drives Random Migration and Disordered
Lamellipodia
To investigate further the behavior of mutant p53-expressing
H1299 cells, we examined their migration in scratch-wound
assays. Control H1299 cells migrated persistently following
wounding and followed paths that were largely perpendicular
to the wound edge (Figure 2A). By contrast, mutant p53-
expressing cells moved erratically into the wound and displayed
a marked loss of persistence, although their migration speed
was unaltered (Figure 2A, Figure S2, and Movies S1–S3).p53fl/+ mice. No difference in median survival was seen between the two groups
PCR172H/+ p53fl/+ mice. (E) shows a superficially invasive adenocarcinoma with
l muscle layers. (F) shows a more advanced tumor, with mucin lakes infiltrating
of the invasive tumors from AhCre APCfl/+ p53fl/+ and AhCre APCfl/+ p53R172H/+
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Figure 2. Mutant p53 Expression Leads to Loss of Persistent Migration and Polarity
(A) Vector control and mutant p53-expressing H1299 cells were observed by time-lapse video microscopy, the movement of individual cells was followed using
cell-tracking software, and this is presented as overlays of representative trajectories described by cells during their migration into the wound. The persistence
(lower right panel) and speed (lower left panel) of migration were extracted from the track-plots. Persistence is defined as the ratio of the vectorial distance trav-
eled to the total path length described by the cell. Values are means ± SEM of >100 track-plots from three independent experiments. * indicates p < 0.05 as
determined by a Student’s t test.
(B) Vector control and mutant p53 H1299 cells were grown in monolayers and wounded. The localization of the Golgi (green) was determined using immune fluo-
rescence and cells were counterstained with phalloidin (red) and DAPI (blue). Scale bars indicate 10 mm. The localization of the Golgi complex in >100 cells at the
edge of the wound and in cells further away from the wound is depicted in the right panel.
(C) Stills taken from movies (Figures S2A, S2B, and S2C) showing the motility of vector control and mutant p53 (175H and 273H) H1299 cells following transfection
with GFP-actin. The data are representatives of three independent experiments of a total of 18 movies. Scale bars represent 20 mm.
See also Figure S2 and Movies S1–S6.Cells orient the Golgi complex to face the direction of migra-
tion when they move into scratch wounds (Kupfer et al., 1982),
and in around 80% of control H1299 cells the Golgi complex1330 Cell 139, 1327–1341, December 24, 2009 ª2009 Elsevier Inc.faced the wound edge (Figure 2B). Conversely, mutant p53 cells
did not consistently orientate their Golgi toward the wounded
area (Figure 2B), indicating the possibility that their random
migration may be associated with an inability to properly estab-
lish an axis of polarity with respect to the wound’s edge.
Fluorescence time-lapse imaging of GFP-actin revealed that
migrating H1299 cells adopted a fan-like morphology in which
an actin-rich lammellipodium advanced in an organized, proces-
sive fashion, with retrograde movement of filaments back from
the leading edge being visible (Figure 2C and Movies S4–S6).
However, the morphology of mutant p53-expressing cells was
markedly altered, with an apparent collapse of the lamellipodium
and instead the presence of disorganized actin-rich ruffles that
displayed alternately protruding and retracting behavior and
that were not concertedly oriented toward the wound edge
(Figure 2C and Movies S4–S6). Taken together these data indi-
cate that expression of mutant p53 proteins in these cells alters
their morphology to favor disorganized random movement on
two-dimensional (2D) surfaces, and this is accompanied by
increased invasiveness in 3D.
Mutant p53 Promotes b1-Integrin-Dependent Cell
Motility and Invasion
The invasive capacity of H1299 and RPE cells was dependent on
the presence of EGF as a chemoattractant (Figure 3A) and fibro-
nectin (Figure 3B) in the Matrigel, suggesting a role for epidermal
growth factor receptor (EGFR) and a fibronectin-binding integrin
(such as a5b1) in mutant p53-dependent invasion. We therefore
examined the effect of a specific a5-integrin-blocking antibody
(mAb16) and an EGFR inhibitor (PD153035) on the invasion of
mutant p53-expressing H1299 cells into fibronectin-containing
Matrigel. Whereas these inhibitors had no effect on the invasive-
ness of control cells, the ability of mutant p53 to drive invasion
was ablated by inhibition of either a5b1 or EGFR (Figure 3C).
Consistently, blockade of b1-integrin (with the AIIB2 antibody
that inhibits all b1-integrin heterodimers, including a5b1) also
abolished the formation of invasive structures by MCF10A cells
(Figure 3D). The ability of mutant p53 to drive random migration
of H1299 cells was also opposed by inhibition of EGFR or a5b1,
which reverted the migratory behavior of mutant p53-expressing
cells to that seen in control cells (Figures 3E and S3). Therefore
the altered migration and enhanced invasion driven by mutant
p53 depends on EGFR signaling and the ability of b1-integrins
to engage their ligands.
There is considerable crosstalk between integrins and the
signaling of receptor tyrosine kinases (RTKs) (Schwartz and
Ginsberg, 2002), so we examined the effect of mutant p53
expression on integrin and EGFR signaling in trypsinized cells
that were either allowed to remain in suspension or were replated
onto fibronectin-coated dishes. Western blotting indicated that
EGFR phosphorylation and activation of AKT (both basally and
following plating onto fibronectin) were markedly higher in
mutant p53-expressing cells, but activity of the MAPK pathway,
as evidenced by phosphorylation of ERK, was less strongly
affected (Figure 3F). These results predict that cells with mutant
p53 would show more active signaling downstream of EGFR,
particularly to AKT. To investigate this directly, we stained tissue
microarrays of human colorectal cancer samples for p53 and
compared this with the levels of active phospho-AKT. We used
high p53 staining as an indication of the presence of potential
gain-of-function p53 mutations—such as the ones under studyChere. In contrast to loss-of-function mutations, these p53
mutants are stable in cancer cells and accumulate in the nucleus
(Soussi, 2000). Consistent with our model, we detected a clear
correlation between elevated p53 staining and high levels of
phospho-AKT (Figure 3G).
Enhanced Recycling and Invasion Is Dependent
on Rab-Coupling Protein
Integrin function and signaling are dictated by the way in which
the heterodimers are trafficked through the endosomal pathway
(Caswell and Norman, 2008; White et al., 2007). We have found
that a5b1 and EGFR recycle to the plasma membrane in
complex with one another, and a consequence of enhanced
cotrafficking of a5b1 and EGFR is random migration on 2D
surfaces and increased invasion into fibronectin-containing
matrices. This is associated with enhanced signaling from
EGFR to the proinvasive kinase, AKT (Caswell et al., 2008). We
therefore compared the internalization and recycling of a number
of receptors in control H1299 cells with those that express
mutant p53. Whereas the rate of receptor internalization was
unaltered (Figure S4A), mutant p53 increased the rate at which
internalized a5b1 and EGFR (but not the transferrin receptor)
returned to the plasma membrane (Figure 4A and Figure S4B).
Furthermore, the ability of mutant p53 to enhance a5b1 recycling
was not a consequence of altered EGFR signaling, as knock-
down of this RTK did not alter a5b1 trafficking (Figure S4C).
We have previously reported that enhancement and coordina-
tion of a5b1 and EGFR trafficking depend on their association
with the Rab11 effector Rab-coupling protein (RCP, Rab11-
FIP1) (Caswell et al., 2008). Consistent with this, we found that
p53-driven recycling of a5b1 and EGFR was completely depen-
dent on RCP, whereas receptor trafficking in control cells was
unaffected by knockdown of RCP (Figure 4B). Furthermore,
knockdown of RCP also opposed the ability of p53 to drive inva-
sion into Matrigel (Figure 4C) and restored the 2D migration
pattern (Figure 4D) and actin dynamics (Figure 4E and Movies
S7–S14) of mutant p53-expressing cells to that of control, p53
null H1299 cells.
The incorporation of RCP into a complex with a5b1 and EGFR
is associated with enhanced recycling of the receptors (Caswell
et al., 2008). Interestingly, we found that although the interaction
of EGFR with RCP was not affected, the presence of mutant
p53 strongly promoted interaction between a5b1 and RCP
(Figure 4F). Importantly, no interaction was observed between
mutant p53 and RCP, suggesting that mutant p53 indirectly
facilitates the recruitment of RCP to a5b1 (Figure 4F) to drive
invasion.
Endogenous Mutant p53 Promotes RCP-Dependent
Invasion
The results presented above depended on ectopic expression
of mutant p53. The levels of mutant p53 expressed in our
engineered H1299 cells were not higher than those seen in
a series of tumor cell lines expressing endogenous mutant p53
(Figure 5A), suggesting that the phenotypes observed were not
due to gross overexpression of the mutant p53. However, we
wished to assess the contribution of endogenous mutant p53
to invasive behavior and so we used A431 cells, which wereell 139, 1327–1341, December 24, 2009 ª2009 Elsevier Inc. 1331
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Figure 3. Invasive Behavior of Mutant p53-Expressing Cells Is Dependent on Integrin/EGFR Signaling
(A and B) The dependence of mutant p53-driven invasion on fibronectin or EGF was determined by plating H1299 vector control or mutant p53 (273H) cells in the
absence of EGF as chemo-attractant (A) or in the absence of fibronectin (B). Values are means ± SEM of 9 replicates from three independent experiments. *
indicates p < 0.05 as determined by a Student’s t test.
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able to invade efficiently into Matrigel supplemented with fibro-
nectin (data not shown and Figure 5B). Previous studies have
shown that the invasion of A431 cells injected into nude mice
was greatly impaired after b1-integrin knockdown (Brockbank
et al., 2005). Accordingly, inhibiting EGFR or a5-integrin signifi-
cantly impeded the invasion of A431 cells (Figure 5B). Impor-
tantly, siRNA-mediated reduction of endogenous mutant p53
or RCP levels efficiently blocked the invasion of these cells
(Figure 5C). Moreover, knockdown of mutant p53 expression
resulted in a reduced recycling of a5b1 and EGFR (Figure 5D),
and an impaired interaction of RCP with a5b1 (Figure 5E), consis-
tent with a role for endogenous mutant p53 in recruitment of
RCP, a5b1, and EGFR1 into a physical complex that facilitates
the return of these receptors to the cell surface.
To confirm that endogenous mutant p53 promotes invasive
behavior, we turned to MDA MB231 cells, which express high
levels of a DNA-binding domain p53 mutant (R280K) that has
lost wild-type activity (Epstein et al., 1998) (Figure 5F). MDA
MB231 cells invade efficiently into both Matrigel and collagen
supplemented with fibronectin, and siRNA depletion of either
endogenous mutant p53 or RCP significantly reduced this inva-
sion (Figure 5G). Taken together, the results in A431 and MDA
MB231 cells support the conclusion that endogenous levels of
mutant p53 drive tumor cell invasion through an RCP-dependent
mechanism.
Invasive Activity of Mutant p53 Correlates
with Inhibition of p63 Function
Previous studies have identified two mechanisms that contribute
to the gain of function of mutant p53, one that requires the
N-terminal trans-activation domain of p53 (Lin et al., 1995; Matas
et al., 2001), and the other reflecting its interaction with family
members p63 or p73 (Li and Prives, 2007). As reported previ-
ously, we detected an interaction between p63 or p73 and
mutant p53 (Figure 6A) (Gaiddon et al., 2001; Strano et al.,
2002), with a stronger interaction of the 175H conformational
mutant compared to the 273H DNA-contacting mutant
(Figure 6A). The interaction between mutant p53 and p63 can
be enhanced in response to TGF-b (Adorno et al., 2009).
However, we did not detect such an increased interaction
(Figure S5A) and we did not observe a significant effect of
TGF-b treatment or inhibition on migration (data not shown),
suggesting that our cells are not sensitive to these effects of
TGF-b.(C) The invasion of mutant p53 (273H) H1299 cells into Matrigel in the presence of
itor (PD 153035), using EGF as chemo-attractant. Values are means ± SEM of 18
mined by a Student’s t test.
(D) Vector control or mutant p53 (175H) MCF10A cells were seeded into collage
(AIIB2) or control immunoglobulin and invasive structures were quantified as for
(E) Representative track-plots were extracted from movies of vector control and
wounds under normal conditions or in the presence of Mab16 or PD 153035.
(F) The activity of the EGFR was determined in attachment assays in which muta
and then plated onto fibronectin (FN) coated surfaces or kept in suspension (S)
(residue 437), and ERK 1/2 was determined by immunoblot analysis using phosph
blot.
(G) Immunostaining of 60 primary human colon cancer sections with antibodies ag
strong and the weighted histoscore used to determine the Spearman correlation
See also Figure S3.
CA series of N-terminal and C-terminal truncations within the
context of p53 175H (Figure 6B) were constructed and exam-
ined. Several previous studies have shown that the interaction
between mutant p53 and p63 is mediated through the central
DNA-binding domain (Gaiddon et al., 2001; Strano et al.,
2002), and we confirmed that both N- and C-terminal deletions
of p53 175H retained p63-binding activity (Figure S5B). To test
the effect of these p53 proteins on p63 activity, we assessed
their ability to inhibit the ability of the TA isoform of p63 (contain-
ing the full-length trans-activation domain within the N terminus)
to drive expression from a p63-responsive promoter (Figure 6C).
As shown previously, mutant p53 expression inhibited TAp63
activity, through a mechanism that did not require the N terminus
of mutant p53. Interestingly, however, the strength of interaction
between the proteins as assessed by coprecipitation was not
a strong indicator of the effectiveness of p63 inhibition by mutant
p53. For example, p53 273H reproducibly decreased TAp63-
dependent transcriptional activity more effectively than p53
175H, despite apparently binding more weakly. Conversely,
the C-terminal truncations of p53 175H and p53 273H (D347
and D370) were less effective in inhibiting TAp63 without a clear
defect in binding (Figures 6B and 6C).
Next, we tested the ability of the p53 truncation mutants to
promote invasion. Deletion (D43) of the N terminus of p53 in
the context of either 175H or 273H did not disrupt the activity
of mutant p53 in this assay (Figure 6D), showing that this trans-
activation domain of p53 is not required. Similarly, a double point
mutant within this domain (22/23) also retained invasive activity
(data not shown). In contrast, C-terminal deletions (D347 and
D370) impaired the ability of the 175H and 273H p53 mutants
to drive invasion (Figure 6D). Thus, the activity of each of the
p53 mutants in the invasion assay correlated with their ability
to inhibit the transcriptional function of TAp63 (Figure 6C).
Loss of p63 Promotes Invasion and Random Migration
Our results suggested that the activity of mutant p53 may reflect
an inhibition of p63 or p73. Loss of p63 or p73 can enhance inva-
sion and transformation in the absence of p53 (Flores et al., 2005;
Lang et al., 2004), and so we tested whether loss of p63 or p73
could substitute for the expression of mutant p53 in our assays.
p63 is expressed as three alternatively spliced isoforms (a, b, and
g) from two promoters that generate full-length or truncated
N termini (TA and DN) (Bourdon, 2007). Using a series of reverse
transcriptase reactions, we determined that H1299 cells expressa monoclonal antibody directed against a5-integrin (Mab16) or an EGFR inhib-
replicates from three independent experiments. * indicates p < 0.05 as deter-
n 1-supplemented Matrigel in the presence of a b1-integrin blocking antibody
Figure 1. Scale bars represent 100 mm.
mutant p53 (175H and 273H)-expressing H1299 cells migrating into scratch
nt p53 (273H) and vector control H1299 cells were trypsinized, serum-starved,
for 30 min. Cells were lysed and phosphorylation of EGFR (residue 845), AKT
o-specific antibodies. Actin expression was used as loading control in a parallel
ainst p53 and p-AKT. Staining was scored blind as absent, weak, moderate, or
between p53 levels and p-AKT staining (right panel).
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mainly TAp63 a and b (data not shown), so we used siRNAs tar-
geted to these isoforms to reduce p63 expression in these cells
(Figure 7A). Inhibition of p63 expression in H1299 cells resulted in
enhanced invasion into Matrigel to levels similar to those seen
following mutant p53 expression (Figure 7A), although reduction
of p63 expression did not further affect invasion by mutant
p53-expressing cells. Also, an siRNA resulting in a partial knock-
down of p63 caused only a partial activation of invasion (Fig-
ure 7A). Furthermore, knockdown of p63 expression led to
random migration in p53 null H1299 cells, as seen in cells
expressing mutant p53 (Figure 7B). By contrast, modulation of
p73 expression by siRNA knockdown in these cells did not
obviously affect invasion (Figure 7A) or random migration (Fig-
ure 7B). As seen following mutant p53 expression, knockdown
of p63 resulted in increased recycling of a5b1-integrin and
EGFR (Figure 7C). Finally, we also found that overexpression of
TAp63a reversed the effects of mutant p53 expression on the
ability of cells to invade into Matrigel (Figure 7D). These results
indicate that inactivation of p63 cooperates with loss of wild-
type p53 to drive integrin recycling, invasion, and random migra-
tion and suggest that these activities of mutant p53 may reflect
its ability to inactivate TAp63. It is important to note, however,
that the effects of modulating p63 are highly context dependent,
with previous studies showing that inhibition of p63 expression in
MCF10A cells (that express only DNp63) results in cell detach-
ment and death (Carroll et al., 2006).
DISCUSSION
This study describes a gain of function of mutant p53 in
promoting both random cell migration and invasion. Underlying
these activities is the ability of mutant p53 to promote recycling
of integrins and EGFR in a way that is dependent on RCP—and
importantly knock down of RCP prevented p53-driven recycling
but had no effect on the basal receptor trafficking in these cells.
Mutant p53 promoted enhanced binding of integrin to RCP, and
since the effect of mutant p53 on integrin recycling did not
depend on EGFR, it seems likely that—as seen in cells treated
with osteopontin (Caswell et al., 2008)—the RTK is recycled to
the plasma membrane as a consequence of the integrin/RCP
interaction, and not vice versa.
Interestingly, RCP has recently been identified as an onco-
gene that can contribute to the aggressiveness of breastFigure 4. RCP Is Required for Mutant p53-Mediated Integrin and EGFR
(A) The recycling of a5b1, EGFR, or the transferrin receptor in vector control or mu
Procedures. Values are means ± SEM of 9 replicates from three independent ex
(B) Vector control or mutant (273H) H1299 cells were transfected with siRNAs t
western blotting (left panel), and actin expression was used as loading control. T
(C) The invasion into Matrigel of vector control or mutant p53 (273H) H1299 cells t
panel). Values are means ± SEM of 18 replicates from three independent experim
(D) Representative track-plots showing the effect of RCP knockdown on the migra
migrating into scratch wounds (left panels). Values of migrational persistence wer
means ± SEM from three independent experiments. * indicates p < 0.05 as dete
(E) Stills from Movies S7–S10, showing the motility of mutant p53 (273H) cells that
monitored by a 5 min time-lapse microscopy 1.5 hr after scratching the wound.
(F) Immunoprecipitation of GFP from vector or mutant p53-expressing H1299 ce
those present in immunoprecipitates (right panel) were determined by western b
See also Figure S4 and Movies S7–S14.
Ccancers by regulating invasion and metastatic potential
(Zhang et al., 2009). Previously we found that RCP-dependent
a5b1/EGFR trafficking augments EGFR phosphorylation,
leading to increased AKT signaling (Caswell et al., 2008). Consis-
tent with this, mutant p53 drives constitutive activation of
EGFR and its communication with AKT (but not ERK). As pre-
dicted by this model, IHC staining of primary human colons
showed a correlation between high expression of p53 (an indi-
cator of the presence of mutant p53) and strong phospho-AKT
staining. These results suggest that mutant p53 specifically
drives RCP-dependent recycling of integrin and EGFR (and
possibly other receptors), resulting in alteration of AKT signaling,
which contributes to increased invasion and metastasis.
Our results support a role for the mutant p53/p63 interaction in
controlling invasion, consistent with previous studies showing
that loss of p63 and/or p73 in the context of p53 deletion might
be functionally equivalent to the expression of mutant p53
(Flores et al., 2005; Lang et al., 2004). p63 plays an important
role in cell adhesion and survival (Carroll et al., 2006), and the
ability of TGF-b to enhance the interaction of p63 with mutant
p53 has been shown to correlate with invasion (Adorno et al.,
2009). Although the activities of mutant p53 described here do
not depend on TGF-b, it will be of interest to determine whether
enhanced integrin recycling driven by mutant p53 might also
affect TGF-b signaling.
Despite compelling evidence that p63 is an important target
for mutant p53, it is clear that expression of mutant p53 is not
equivalent to loss of p63 under all circumstances—as illustrated
by MCF10A cells that show enhanced invasion following expres-
sion of mutant p53, but loss of attachment, detachment, and
death in response to p63 depletion (Carroll et al., 2006). This
may be due to which isoforms of p63 are expressed, since the
function of TAp63 that is expressed in H1299 cells is likely to
be different from that of DNp63 expressed in MCF10A cells.
Intriguingly, mutant p53 expression also prevents the loss of
integrin expression that normally occurs following matrix
detachment of MCF10A cells, and it is tempting to evoke a role
for additional activities of mutant p53 that may be independent
of p63 (Brosh and Rotter, 2009).
Our results show that the ability of mutant p53 proteins to
contribute to the development of invasive and metastatic
cancers in vivo is paralleled by their ability to enhance RCP-de-
pendent recycling of integrin, thereby promoting trafficking andRecycling
tant p53 (273H) H1299 cells was determined as described in the Experimental
periments.
argeting RCP or a nontargeting control (ctr). RCP levels were determined by
he recycling of a5b1 or EGFR was determined as for (A) (right panels).
hat were transfected with siRNAs targeting RCP or a nontargeting control (right
ents. * indicates p < 0.05 as determined by a Student’s t test.
tion of vector control and mutant p53 (175H and 273H)-expressing H1299 cells
e extracted from the track-plots as for Figure 2A (lower right panel). Values are
rmined by a Student’s t test.
were transfected with siRNAs targeting RCP in combination with GFP-actin and
Scale bars represent 20 mm.
lls transfected with GFP or GFP-RCP. The input protein levels (left panel) and
lotting.
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signaling of growth factor receptors. This can drive both random
migration and invasion, and the precise response to mutant
p53 expression will be influenced by the cellular context.
While mutant p53 has other activities that can impinge on cell
behavior and survival (Brosh and Rotter, 2009), our study
provides an understanding of the molecular details of at least
one aspect of the invasive behavior of mutant p53, an important
first step to the design of therapies that might interfere with this
activity.EXPERIMENTAL PROCEDURES
Cell Culture and Constructs
H1299, A431, SK-BR3, SW480, MDA MB231, RPE, and MCF10A cells were
cultured as described in the Supplemental Experimental Procedures. For the
generation of stable cell lines, H1299, RPE, and MCF10A cells were trans-
fected with an empty vector (PCB6+) or constructs expressing p53175H or
273H (in PCB6+; 72R polymorphism) with effectene reagent (QIAGEN). Cells
were selected by medium containing 600 mg/ml G418. p53 mutants have
been previously described or created using site-directed mutagenesis, as
detailed in the Supplemental Data.Inverted Invasion Assays
Matrigel or collagen assays were performed as described previously (Caswell
et al., 2008) and in the Supplemental Experimental Procedures. Briefly, cells
were seeded on the base of matrigel or collagen-filled transwell chambers
and invasion toward a gradient of 10% FCS and 25 ng/ml EGF was measured
by confocal microscopy in serial sections.Immunoprecipitation and Immunblot Analyses
p53 and GFP-RCP were immunoprecipitated from lysates of transfected cells
using the 1801 and anti-GFP (Abcam) antibodies, respectively. Details of the
protocol and source of antibodies used for immunoblotting are provided in
the Supplemental Experimental Procedures.Scratch-Wound Assays, Fluorescence Time-Lapse,
and Immunofluorescence
Movement of cells into a wound scratched into a monolayer and grown in 1%
FCS was monitored with a phase contrast 203 objective using an inverted
microscope (Nikon TE2000). Images were obtained every 10 min for the dura-
tion of 16 hr.
Cells transfected with GFP-actin and siRNAs were scratched and actin
behavior assessed using an inverted confocal fluorescence microscope (Fluo-
view FV1000, Olympus), taking pictures every 10 s for 5 min. Immunofluores-
cent imaging of the Golgi was carried out using a GM-130 antibody.Figure 5. Downregulation of Endogenous Mutant p53 Expression Red
(A) The exogenous expression of mutant p53 in H1299 cells compared with the ex
used as loading control in a parallel blot.
(B) The invasion of A431 cells in the presence of PD153035 or Mab16 into Matrigel
* indicates p < 0.05 as determined by a Student’s t test.
(C) A431 cells were transfected with siRNAs targeting p53 or RCP and their inv
depicted in the right panel (on parallel blots), with actin used as loading control, on
experiments. * indicates p < 0.05 as determined by a Student’s t test.
(D) A431 cells were transfected with siRNAs targeting endogenous mutant p53 an
(E) Immunoprecipitation of GFP from control or mutant p53 knockdown A431 ce
those present in immunoprecipitates (right panel) were determined by western b
(F) The endogenous expression of mutant p53 in MDA MB231 cells compared t
loading control.
(G) The invasion of MDA MB231 cells transfected with siRNA directed against p5
18 replicates from three independent experiments. * indicates p < 0.05 as determ
right panel (on parallel blots); actin was used as loading control on the RCP blot
CTumor Formation In Vivo
Female CD1 nude mice were obtained from Charles River (Margate Kent) and
all experiments were carried out according to Home Office regulations. To
study igenesis, in total 20 mice were divided in 2 groups of 10 mice that
were injected with stably transfected vector control H1299 or mutant p53
273H H1299. 1 3 106 cells were washed in HBS and diluted in Matrigel (1:1)
and 100 ml of this mixture was injected into the fat pad. Every 2 to 3 days diam-
eters were measured and when they reached a 1.7 cm diameter, primary
tumors, mammary lymph nodes, mammary tissue, and lungs were harvested
for immune histochemistry. Tissues were fixed in paraformaldehyde and
stained with hematoxylin and eosin (H&E).
For intestinal tumorigenesis experiments, AhCre, Apc580 s (referred to as
Apcfl) (Sansom et al., 2004), p53fl (Jonkers et al., 2001), and Lox stop lox
p53R172H (Olive et al., 2004) alleles were used. Mice had been backcrossed
to C57BlJ for at least five generations. Mice were given three injections of
b-napthoflavone in a single day at 6–8 weeks of age to induce near 100%
recombination within the intestinal epithelium (Sansom et al., 2006). Intestinal
tumors develop in this model through loss of the remaining wild-type Apc
allele. Mice were aged until they developed signs of intestinal disease, namely
paling of feet due to anemia, weight loss, and hunching. At this stage, intes-
tines were removed, flushed with PBS, and opened en face. Tumor number
and size were then scored macroscopically and intestines fixed as previously
described (Sansom et al., 2004).
Tissue Microarrays
Zymed’s MaxArray Human Colon Carcinoma Tissue Microarray slides (Invitro-
gen, 75-4033) containing 60 tissue samples were deparaffinized and rehy-
drated according to manufacturer’s instructions. Staining intensities were
analyzed using the Spearman’s rank correlation coefficient.
Receptor Internalization and Recycling Assays
Internalization and recycling of a5b1, EGFR, and transferrin were determined
in cells transfected with the appropriate siRNAs and serum starved for
30–45 min before the start of the experiment, as previously described (Caswell
et al., 2008; Roberts et al., 2001).
Quantitative RT-PCR
To assess mRNA levels, RNA was isolated from cells using a QIAGEN kit or
Trizoll reagent, and cDNA synthesized using the Invitrogen kit. For the RT-PCR
reaction, 5 ml of the 40 times diluted cDNA was used in combination with 10 ml
Sybr green Mastermix, 1 ml of each oligo (10 mM) as described in the Supple-
mental Experimental Procedures.
p63 Luciferase Reporter Assays
Cells were transfected with 300 ng K14 Firefly luciferase and 30 ng Renilla
luciferase constructs, together with p63 and p53 expression constructs as
described in the figure legends and Supplemental Experimental Procedures.
Firefly luciferase measurements were corrected for Renilla luciferase values
and expressed as relative light units (RLU).uces RCP-Dependent Invasion
pression of endogenous mutant p53 in various cell lines. Actin expression was
. Values are means ±SEM of 18 replicates from three independent experiments.
asiveness into Matrigel was determined. The expression of p53 and RCP is
the RCP blot. Values are means ±SEM of 18 replicates from three independent
d the recycling of a5b1 or EGFR, and p53 expression levels were determined.
lls transfected with GFP-RCP or GFP. The input protein levels (left panel) and
lotting.
o the expression of mutant p53 in transfected H1299 cells. Actin was used as
3 or RCP into Matrigel (top) or collagen (bottom). Values are means ± SEM of
ined by a Student’s t test. The expression of p53 and RCP is depicted in the
.
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Figure 6. Mutant p53 Proteins that Drive Invasion Inhibit p63 Activity
(A) Immunoprecipitation of p53 in H1299 cells transfected with HA-TAp63 alpha, HA-DNp63 alpha, or HA-p73 in combination with a vector control, wild-type (WT)
p53, p53 175H, or p53 273H.
(B) Cartoon depicting the position of the targeted deletions in mutant p53.
(C) H1299 cells were transfected with K14 Firefly luciferase, TK Renilla luciferase, and p63 in combination with decreasing concentrations of the indicated p53
constructs. Firefly luciferase activity was corrected for Renilla luciferase expression and the values are means ± SEM from three independent experiments. The
expression of HA-p63 and the expression of (mutant) p53 were determined in immunoblot analysis and actin was used as loading control, on a parallel blot.
(D) The invasion into Matrigel of H1299 cells (left panel) transfected with the indicated p53 proteins (right panel). Invasion is expressed relative to p53-negative
control cells. Values are means ± SEM of 18 replicates from three independent experiments. * indicates p < 0.05 as determined by a Student’s t test.
See also Figure S5.
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Figure 7. p63, but Not p73, Controls Invasion and Persistence of Migration
(A) The invasion of control or mutant p53 (273H) H1299 cells that were transfected with two different siRNAs targeted against p63 or an siRNA targeted against
p73 was measured (left panel) and quantified (upper right panel). Values are means ± SEM of 18 replicates from three independent experiments. * indicates p <
0.05 as determined by a Student’s t test. The mRNA expression of p63 was determined by RT-PCR analysis (lower right panel). The relative expression in control
cells was designated as 1 and values were corrected for GAPDH expression.
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SUPPLEMENTAL DATA
Supplemental Data include five figures, Supplemental Experimental Proce-
dures, and 14 movies and can be found with this article online at http://
www.cell.com/supplemental/S0092-8674(09)01438-X.
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